Synapsoft logo
AI Insights from Disclosures
Searching...
D&D Pharmatech Inc. 347850
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
D&D Pharmatech Inc. is a company that researches and develops innovative new drugs for disease groups with high unmet medical needs, such as metabolic diseases including obesity and MASH (metabolic dysfunction-associated steatohepatitis), and degenerative brain diseases, based on peptide-related technologies such as GLP-1. The company holds a diverse new drug pipeline including its core GLP-1-based pipeline assets, (1) oral obesity treatments (DD02S, DD03, etc.) and (2) a MASH treatment (DD01), as well as the Parkinson's and Alzheimer's disease treatment NLY01 and the fibrotic disease treatment TLY012.
Representative Director Lee Seulgi
Founded November 28, 2014
Corporation Type KOSDAQ
Industry Classification Research and experimental development on medical sciences and pharmacy
Corporate number 11011-5575662
Business number 120-88-21933
Phone Number 031-8019-7771
Fax Number 031-8019-7772
Company Address 27 Geumto-ro 80beon-gil, Sujeong-gu, Seongnam-si, Gyeonggi-do
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant